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Objective: This study aimed to compare the glucose-lowering effect and glycemic variability 
of insulin glargine with those of insulin detemir.
Material and methods: This was an open-label, single-center, randomized, two-way crossover 
study in patients with diabetes on basal-bolus insulin therapy, with neutral protamine Hagedorn 
(NPH) insulin as basal insulin. Patients switched from NPH insulin to a course either of insulin 
glargine followed by insulin detemir, or insulin detemir followed by insulin glargine, continuing 
the same dose of the prior bolus of insulin. To evaluate the glucose-lowering effect, daily glycemic 
profiles were recorded for 72 hours by continuous glucose monitoring (CGM) in an outpatient 
setting. The mean amplitude of glycemic excursions, standard deviation (SD), and the mean of 
daily difference (MODD) were used to assess intraday and day-to-day glycemic variability.
Results: Eleven patients were enrolled and nine completed the study. Mean blood glucose cal-
culated from CGM values was significantly lower with insulin glargine compared with insulin 
detemir (9.6 ± 2.4 mmol/L versus 10.4 ± 2.8 mmol/L, P = 0.038). The SD was significantly 
lower with insulin glargine versus insulin detemir (2.5 ± 0.9 mmol/L vs 3.5 ± 1.6 mmol/L, 
P = 0.011). The MODD value was significantly lower with insulin glargine than with insulin 
detemir (2.2 ± 1.1 mmol/L vs 3.6 ± 1.7 mmol/L, P = 0.011). There was no significant difference 
between the two insulin analogs in terms of hypoglycemia.
Conclusion: This study suggests that insulin glargine leads to more effective and more stable 
glycemic control than the same dose of insulin detemir.
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Introduction
The Diabetes Control and Complications Trial1 and the Kumamoto Study2 have shown 
that intensive insulin therapy and the resulting improvements in glycemic control reduce 
the incidence and delay the progression of microvascular complications. However, 
neutral protamine Hagedorn (NPH) insulin, which was used as basal insulin in these 
studies, has several limitations. Of note, its duration of action is only 8–12 hours, 
with a peak in action occurring within 4–6 hours after subcutaneous administration, 
thus increasing the risk of hypoglycemia.3–7 Indeed, some patients complain of hypo-
glycemia before dawn, necessitating a reduction in the NPH insulin dose at bedtime. 
However, reducing the NPH insulin dose at bedtime increases the blood glucose level 
in the morning. Additionally, NPH insulin is a suspension, which must be thoroughly 
resuspended before injection, and inadequate resuspension results in a very large 
  day-to-day glycemic variability of action.8,9 Therefore, to achieve tight glycemic control 
without increasing the risk of hypoglycemia, insulin preparations with a long duration Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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of action and low day-to-day glycemic variability in terms of 
glucose-lowering action are needed.
Insulin glargine4,6,10 and insulin detemir5,7,11,12 are basal 
insulin analogs of the dissolution type that have flatter profiles 
and longer duration of action compared with NPH insulin. 
However, there is controversy over which insulin analog has 
the longer and more stable action. Therefore, in this study, the 
aim was to compare the glucose-lowering effect and glycemic 
stability of insulin glargine with those of insulin detemir using 
continuous glucose monitoring (CGM).
Material and methods
Patients
Diabetic patients who were prescribed basal-bolus insulin 
therapy with NPH insulin as basal insulin at bedtime for 
1 year or more were enrolled in the study. Patients who 
injected NPH insulin two or more times per day, with protei-
nuria .1.0 g/day, serum creatinine .132 µmol/L (men) or 
106 µmol/L (women), abnormal aspartate aminotransferase/
alanine aminotransferase elevation (.3 × the upper limit of 
normal), myocardial infarction or stroke within 6 months 
prior to study entry, or HbA1c . 10.0% or ,5.8%, were 
excluded from this study.
All patients received an explanation of the procedures 
and possible disadvantages of participating in the study and 
gave written informed consent prior to entry. This study 
was approved by the Institutional Review Board of Kitasato 
Institute Hospital and was performed in accordance with the 
Declaration of Helsinki.
Design of the study
Patients were randomized using a computer to either Sequence 
A (NPH insulin was first switched to insulin glargine, then 
to insulin detemir) or Sequence B (insulin detemir followed 
by insulin glargine). The patient’s prior NPH insulin was 
discontinued and replaced with the allocated long-acting 
insulin analog (insulin glargine or insulin detemir). Patients 
were asked to continue their other antihyperglycemic medi-
cations and to not change their dosage throughout the study. 
To compare insulin glargine with insulin detemir under the 
same conditions, the dose of the long-acting insulin analogs 
was the same as that of NPH, and the doses of bolus insulin 
(insulin lispro or insulin aspart) were not changed. The study 
drugs were injected at bedtime. The CGM examination, of 
72 hours in duration from 12 pm on day 1 to 12 pm on day 4, 
was carried out at least 5 days after switching insulin. The 
study drugs were crossed over on the day when the first CGM 
examination ended.
The CGM sensor (CGMS® System Gold; Medtronic, 
Northridge, CA) was applied to the abdominal area by a 
certified diabetologist. Patients were instructed to mea-
sure their capillary blood glucose using finger sticks, at 
least four times per day (at mealtimes and at bedtime). 
Glucose meters were calibrated immediately before 
starting CGM. All patients used the CGM in outpatient 
settings.
glycemic control
The outcomes of this study included determining the 
effectiveness of each type of insulin on glycemic control 
and glycemic variability. Glycemic control was estimated 
as the mean blood glucose (MBG), the area under the 
glucose curve above 7.8 or 10.0 mmol/L (area under the 
curve [AUC].7.8,10), and the percentage of time above 7.8 
or 10.0 mmol/L (t.7.8,10). The AUC was calculated using the 
trapezoidal method.
glycemic variability
Intraday glycemic variability was assessed as the standard 
deviation (SD) and the mean amplitude of glycemic excur-
sions (MAGE). The SD around the mean glucose values 
is considered the “gold standard” assessment of intraday 
glycemic variability.13 MAGE, described by Service et al,14 
is probably more appropriate for selecting the major glucose 
swings that are calculated as the arithmetic mean of differ-
ences between consecutive peaks and nadirs, provided that 
the differences are greater than the SD around the mean 
values.13
Day-to-day glycemic variability was assessed as the 
mean of daily difference (MODD). MODD, described 
by Molnar et al,15 is the mean of the absolute difference 
between glucose values taken on 2 consecutive days at the 
same time.
hypoglycemia
Hypoglycemia, which was defined as a sensor value 
of #3.9 mmol/L, was also calculated as a total time 
at #3.9 mmol/L. Severe hypoglycemia was defined as a 
sensor value of #2.8 mmol/L.
Statistical analysis
All values are shown as means with SD. The differences 
between two insulin analogs were analyzed using the Wil-
coxon rank-sum test. A P value of ,0.05 was considered 
statistically significant. SPSS software 14.0J (SPSS Japan 
Inc, Tokyo, Japan) was used for all   statistical analyses.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Table 1 Patient demographics and baseline characteristics
Type of diabetes (type 1/type 2) 4/5
gender (male/female) 3/6
Age (years) 64 ± 13
Diabetes duration (years) 17 ± 11
Duration of insulin therapy (years) 9 ± 8
Weight (kg) 57.6 ± 8.0
BMi (kg/m2) 24.2 ± 4.9
hbA1c (%) 7.9 ± 1.7
Fasting serum c-peptide (nmmol/L) 0.29 ± 0.25
Total insulin dose (U/kg/day) 0.68 ± 0.19
  Basal insulin dose (U/kg/day) 0.24 ± 0.11
  Bolus insulin dose (U/kg/day) 0.44 ± 0.10
Oral glucose-lowering drugs (n)
  Metformin 1
  Alpha glucosidase inhibitor 3
Note: Data are mean ± SD.
Abbreviations: BMi, body mass index; hb A1c, hemoglobin A1c.
Results
Patient characteristics
A total of eleven Japanese patients, six with type 1 and five 
with type 2 diabetes, were enrolled between May 2008 and 
June 2009. Because of an alert for insulin glargine issued by 
the European Association for the Study of Diabetes,16 this 
study was discontinued and the available data was analyzed. 
Two patients were excluded from analysis because of pro-
tocol violation (misuse of NPH). Therefore, nine patients 
(five in Sequence A and four in Sequence B) completed the 
study. The demographic and baseline characteristics of these 
patients are shown in Table 1.
glycemic control
MBG, as calculated from CGM values, was significantly 
lower with insulin glargine than with insulin detemir 
(9.6 ± 2.4 mmol/L versus 10.4 ± 2.8 mmol/L, P = 0.038) 
(type 1: 11.0 ± 2.5 mmol/L versus 12.2 ± 2.7 mmol/L; type 2: 
8.4 ± 1.8 mmol/L versus 9.0 ± 2.2 mmol/L). Figure 1 shows 
the mean daily profiles of day 2 and day 3. This difference 
between the two insulin analogs was particularly evident 
at nighttime. In addition, AUC>10 and AUC>7.8 were sig-
nificantly lower with insulin glargine versus insulin detemir 
(Table 2).
glycemic variability
The SD was significantly lower with insulin glargine 
than with insulin detemir. However, the MAGE value 
was not significantly different between the two insulin 
analogs (Table 3). The MODD value was significantly 
lower with insulin glargine than with insulin detemir 
(2.2 ± 1.1 mmol/L vs 3.6 ± 1.7 mmol/L, P = 0.011;   Figure 2) 
(type 1: 2.7 ± 1.2 mmol/L vs 4.7 ± 1.8 mmol/L; type 2: 
1.8 ± 0.9 mmol/L vs 2.7 ± 0.9 mmol/L).
hypoglycemia
There was no difference between the two insulin analogs in 
terms of the total hypoglycemic time. This lack of a differ-
ence remained even after separating the results according to 
daytime and nighttime values. Severe hypoglycemic time was 
also similar for both insulin analogs (Table 2).
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Figure 1 24-hour glucose profiles of day 2 and day 3. Each point represents the mean ± standard deviation of nine patients treated with insulin glargine () or detemir ().Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Figure 2 comparison of the mean of daily difference (MODD) in nine patients 
treated with insulin glargine or detemir. The MODD value was significantly lower 
with insulin glargine than with insulin detemir.
Note: *P = 0.011.
Table 3 comparison of the intraday glycemic variability of glargine 
with that of detemir
Glargine Detemir P value
SD (mmol/L) 2.5 ± 0.9 3.5 ± 1.6 0.011
  Type 1 3.2 ± 0.8 4.6 ± 1.6 0.081
  Type 2 2.0 ± 0.6 2.6 ± 1.0 ns
MAge (mmol/L) 6.3 ± 2.4 7.8 ± 3.6 0.086
  Type 1 7.8 ± 1.7 10.1 ± 3.4 ns
  Type 2 5.1 ± 2.2 5.9 ± 2.7 ns
MODD (mmol/L) 2.2 ± 1.1 3.6 ± 1.7 0.011
  Type 1 2.7 ± 1.2 4.7 ± 1.8 ns
  Type 2 1.8 ± 0.9 2.7 ± 0.9 ns
Note: Data are mean ± SD.
Abbreviations: MAge, mean amplitude of glycemic excursions; MODD, mean of 
daily difference; ns, not significant.
Table  2  comparison  of  glargine  cgM  data  with  detemir 
cgM data
Glargine Detemir P value
Glycemic control
MBg (mmol/L) 9.6 ± 2.4 10.4 ± 2.8 0.038
  Type 1 11.0 ± 2.5 12.2 ± 2.7 ns
  Type 2 8.4 ± 1.8 9.0 ± 2.2 ns
AUc.10 (mmol/L/day) 1.2 ± 1.5 2.1 ± 2.0 0.011
  Type 1 2.1 ± 1.7 3.5 ± 1.9 0.068
  Type 2 0.5 ± 0.9 1.0 ± 1.3 0.080
AUc.7.8 (mmol/L/day) 2.4 ± 2.1 3.3 ± 2.5 0.008
  Type 1 3.6 ± 2.2 5.0 ± 2.3 0.068
  Type 2 1.4 ± 1.5 2.0 ± 1.7 0.043
t.10 (%) 37.6 ± 31.4 44.3 ± 28.6 0.051
  Type 1 57.2 ± 26.3 61.7 ± 24.4 ns
  Type 2 21.9 ± 27.6 30.5 ± 25.5 0.080
t.7.8 (%) 61.9 ± 24.1 63.8 ± 21.1 ns
  Type 1 75.1 ± 19.2 72.3 ± 19.1 ns
  Type 2 51.4 ± 23.9 57.1 ± 22.0 ns
Hypoglycemic
Total hypoglycemic (t,3.9) time (min)
Overtime 64 ± 81 97 ± 177 ns
  Type 1 94 ± 89 65 ± 60 ns
  Type 2 40 ± 74 122 ± 241 ns
nighttime 42 ± 74 19 ± 48 ns
  Type 1 83 ± 99 43 ± 69 ns
  Type 2 10 ± 22 0 ± 0 ns
Severe hypoglycemic (t,2.8) time (min)
Overtime 18 ± 49 6 ± 11 ns
  Type 1 38 ± 75 11 ± 16 ns
  Type 2 3 ± 4 2 ± 4 ns
nighttime 17 ± 50 16 ± 48 ns
  Type 1 38 ± 75 36 ± 73 ns
  Type 2 0 ± 0 0 ± 0 ns
Note: Data are mean ± SD.
Abbreviations: MBg, mean blood glucose; AUc, area under the curve; cgM,     
continuous glucose monitoring; ns, not significant.
Discussion
In this study, the glucose-lowering effect and glucose stabil-
ity of insulin glargine was compared with those of insulin 
detemir using CGM. Glycemic control parameters, such 
as MBG, AUC.10, and AUC.7.8, were better with insulin 
glargine than with insulin detemir. The present study sug-
gests that insulin glargine has a greater glucose-lowering 
effect than insulin detemir at the same dose. The difference 
in glucose-lowering effect can be compensated for by increas-
ing the insulin dose but there might be a difference in the 
cost-effectiveness and hypoglycemic episode. Because the 
same tendency was found in both type 1 and type 2 diabetes 
(MBG in type 1: insulin glargine, 11.0 ± 2.5 mmol/L versus 
insulin detemir, 12.2 ± 2.7 mmol/L; type 2: 8.4 ± 1.8 mmol/L 
versus 9.0 ± 2.2 mmol/L), to maintain statistical power, the 
two types of diabetes were not distinguished.
However, the hypoglycemic time was comparable for 
both of the two insulin analogs. These findings suggest 
that, if higher doses of insulin detemir are administered to 
achieve equivalent glycemic control to insulin glargine, the 
hypoglycemic time might increase.
Furthermore, the intraday and day-to-day glycemic vari-
ability of insulin glargine was compared with those of insulin 
detemir. The results of CGM revealed that SD and MODD 
were lower with insulin glargine than with insulin detemir. 
These findings suggest that insulin glargine might have bet-
ter glycemic variability compared with insulin detemir. It is 
expected that the risk of hypoglycemia is lower with insulin 
glargine than with insulin detemir, if the aim of treatment is 
near-normal glycemia.
Several previous studies have compared insulin glargine 
with insulin detemir.17–29 Three studies using insulin-clamp 
tests yielded very conflicting results.17–19 Heise et al reported 
that the same doses (0.4 U/kg) of insulin glargine and insulin 
detemir are very similar in terms of the mean shape of their Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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authors’ believe this conclusion may be robust. Second, the 
doses of basal insulin used in the present study were different 
from those used in the earlier clinical studies. The average 
basal insulin dose was 0.24 U/kg/day in this study (type 1: 
0.22 U/kg/day; type 2: 0.26 U/kg/day), which was much 
lower than in earlier clinical studies (insulin glargine: 0.3321–
0.7525 U/kg/day; insulin detemir: 0.4021–0.8223 U/kg/day). 
However, these studies were performed in European coun-
tries or in the USA. The doses of basal insulin used in our 
study are similar to those used in the Japanese national phase 
III program for insulin glargine for Japanese patients with 
type 1 diabetes (mean: 0.21 U/kg/day)30 and insulin detemir 
for Japanese patients with type 1 or type 2 diabetes (mean: 
0.27 U/kg/day).31 Therefore, the insulin dose in the present 
study appears to be appropriate for Japanese patients.
Conclusion
The results of the present study suggest that insulin glargine 
provides more effective and more stable glycemic control 
than insulin detemir. Because this study was too small to 
make a final conclusion, however, large-scale studies are 
required to confirm these findings.
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